Autolus Therapeutics is a spin out of UCL Business which incorporated Cancer Research UK licensed IP at formation.
Healthcare investor Syncona on Monday said its portfolio company Autolus Therapeutics had agreed a collaboration and $250m financing deal with Blackstone Life Sciences.
The financing agreement includes $100m of immediate equity investment and up to $150 million in product financing.
Blackstone would appoint a member to the Autolus board and receive a capped mid-single digit royalty based on product revenues, Syncona said in a statement.
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of hematological cancers and solid tumors.